What is HC Wainwright's Forecast for PRAX Q3 Earnings?

Key Points

• HC Wainwright has revised its Q3 2025 earnings estimate for Praxis Precision Medicines to ($3.78), up from a previous estimate of ($4.28).
• Prax's stock currently holds a consensus rating of “Moderate Buy”, with an average price target of $95.22 from various analysts.
• The company's latest quarterly earnings report showed a loss of ($3.31) EPS, which beat analysts' expectations of ($3.40) EPS.

Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) - Equities research analysts at HC Wainwright lifted their Q3 2025 earnings per share (EPS) estimates for shares of Praxis Precision Medicines in a report issued on Tuesday, August 5th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of ($3.78) for the quarter, up from their prior forecast of ($4.28). HC Wainwright currently has a "Buy" rating and a $115.00 target price on the stock. The consensus estimate for Praxis Precision Medicines' current full-year earnings is ($10.22) per share. HC Wainwright also issued estimates for Praxis Precision Medicines' Q4 2025 earnings at ($4.25) EPS, FY2025 earnings at ($14.63) EPS, Q1 2026 earnings at ($4.23) EPS, Q2 2026 earnings at ($4.50) EPS, Q3 2026 earnings at ($4.60) EPS, Q4 2026 earnings at ($4.64) EPS, FY2026 earnings at ($17.98) EPS, FY2027 earnings at ($15.86) EPS and FY2028 earnings at ($7.64) EPS.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported ($3.31) earnings per share for the quarter, topping the consensus estimate of ($3.40) by $0.09. Praxis Precision Medicines had a negative return on equity of 60.07% and a negative net margin of 2,137.48%.

A number of other brokerages also recently issued reports on PRAX. Wedbush upped their price target on Praxis Precision Medicines from $26.00 to $28.00 and gave the company an "underperform" rating in a report on Monday, May 5th. Oppenheimer lifted their price objective on Praxis Precision Medicines from $97.00 to $115.00 and gave the stock an "outperform" rating in a report on Tuesday, July 8th. Needham & Company LLC reaffirmed a "buy" rating and issued a $80.00 price objective on shares of Praxis Precision Medicines in a report on Thursday, June 12th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $80.00 price objective on shares of Praxis Precision Medicines in a report on Tuesday, July 29th. One equities research analyst has rated the stock with a sell rating and eight have issued a buy rating to the stock. According to data from MarketBeat, Praxis Precision Medicines currently has a consensus rating of "Moderate Buy" and a consensus target price of $95.22.

Praxis Precision Medicines Stock Performance

Shares of NASDAQ:PRAX traded down $1.26 during midday trading on Thursday, reaching $44.69. 491,026 shares of the company's stock traded hands, compared to its average volume of 451,111. The company has a market cap of $940.62 million, a price-to-earnings ratio of -3.64 and a beta of 2.62. Praxis Precision Medicines has a one year low of $26.70 and a one year high of $91.83. The stock has a 50 day moving average of $48.11 and a 200 day moving average of $47.85.

Hedge Funds Weigh In On Praxis Precision Medicines

Large investors have recently made changes to their positions in the business. Nisa Investment Advisors LLC lifted its position in shares of Praxis Precision Medicines by 88.3% in the second quarter. Nisa Investment Advisors LLC now owns 629 shares of the company's stock valued at $26,000 after acquiring an additional 295 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Praxis Precision Medicines in the fourth quarter worth about $30,000. CWM LLC lifted its position in shares of Praxis Precision Medicines by 877.9% in the second quarter. CWM LLC now owns 753 shares of the company's stock worth $32,000 after buying an additional 676 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Praxis Precision Medicines by 6,075.4% in the first quarter. GAMMA Investing LLC now owns 4,014 shares of the company's stock worth $152,000 after buying an additional 3,949 shares in the last quarter. Finally, Graham Capital Management L.P. purchased a new stake in shares of Praxis Precision Medicines in the fourth quarter worth about $209,000. 67.84% of the stock is currently owned by hedge funds and other institutional investors.

Praxis Precision Medicines Company Profile

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.